We are transitioning to our new website at www.neb.com, which will go live on April 7th, 2025.

On April 2nd at 8:00 PM ET, www.neb.ca e-commerce functionality will be disabled for the website transition. If you need to place your order between April 2nd at 8:00 pm ET to April 6th, then please call 1-800-387-1095 or email orders.ca@neb.com.

The transition to the new website will not affect our shipping schedule. If you're a registered user, all your account details, including order history and shipping details will be safely transferred to the new site.

Vaccinia Capping System

Catalog # Concentration Size List Price Quantity Your Price
M2080S 10000 units/ml 400 units $219.00
$197.10
Catalog # Size List Price Your Price
M2080S 400 units $219.00
$197.10
Catalog #
Qty:
 
*On-line ordering is for Canadian customers only. Web pricing is applicable only to orders placed online at www.neb.ca

A full system for enzymatic capping based on the Vaccinia virus Capping Enzyme (VCE)

  • Adds 7-methylguanylate cap structures (Cap-0) to the 5′ end of RNA generated by in vitro transcription
  • Cap-0 is required for efficient translation of the RNA in eukaryotic systems
  • mRNA Cap 2´-O-Methyltransferase (NEB #M0366) is required to generate Cap-1 structure that reduces cellular innate immune response when the RNA is used in vivo
  • Isolated from a recombinant source
  • Tested for the absence of endonucleases, exonucleases, RNases
  • Getting ready to scale up RNA synthesis? Download our new technical note “Scaling of High-Yield In vitro Transcription Reactions for Linear Increase of RNA Production” for a generalized set of recommendations for synthesizing high yields of RNA.
Featured Videos
View Video Library

Based on the Vaccinia virus Capping Enzyme (VCE), the Vaccinia Capping System provides the necessary components to add 7-methylguanylate cap structures (Cap-0) to the 5´end of RNA (1). In eukaryotes, these terminal cap structures are involved in stabilization (2), transport (3), and translation (4) of mRNAs. Enzymatic production of capped RNA is an easy way to improve the stability and translational competence of RNA used for in vitro translation, transfection, and microinjection. Alternatively, use of labeled GTP in a reaction provides a convenient way to label any RNA containing a 5´ terminal triphosphate.

Vaccinia capping enzyme is composed of two subunits (D1 and D12). The D1 subunit carries three enzymatic activities (RNA triphosphatase, guanylyltransferase and guanine methyltransferase); all necessary for addition of a complete Cap-0 structure, m7Gppp5'N to 5' triphosphate RNA (5,6). In vitro transcripts can be capped in less than one hour in the presence of the capping enzyme, reaction buffer, GTP, and the methyl donor, SAM. Capping is nearly 100% efficient and all capped structures are added in the proper orientation, unlike co-transcriptional addition of some cap analogs (7).

Figure 1. 5´ Cap Structure



Schematic representation of mRNA 5´ cap structure indicating the 7-methylguanosine, shown in yellow, and the 5´ end of the mRNA, shown in blue. The 2´-O-methyl group present in Cap-1 and Cap-2 structures is shown in red.
Product Source
An E. coli strain that carries an engineered His-tagged Vaccine capping gene.
Reagents Supplied

The following reagents are supplied with this product:

NEB # Component Name Component # Stored at (°C) Amount Concentration
  Vaccinia Capping System M2080SVIAL -20 1 x 0.04 ml 10,000 units/ml
  Capping Buffer B2080AVIAL -20 1 x 0.1 ml
  S-adenosylmethionine (SAM) B9003SVIAL -20 1 x 0.1 ml 32 mM
  GTP N2080AVIAL -20 1 x 0.05 ml 10 mM
Application Features
Capping mRNA prior to translation assays/in vitro translation
Labeling 5´ end of mRNA
Vaccinia Capping System | New England Biolabs
Home RNA Synthesis and Modification Products Vaccinia Capping System

Vaccinia Capping System
NEBU recombinant 37 SAM

GMP-grade reagent also available. Learn more.

Looking for higher capping efficiency and a broader temperature range? Try our new Faustovirus Capping Enzyme.

A full system for enzymatic capping based on the Vaccinia virus Capping Enzyme (VCE)

  • Adds 7-methylguanylate cap structures (Cap-0) to the 5′ end of RNA generated by in vitro transcription
  • Cap-0 is required for efficient translation of the RNA in eukaryotic systems
  • mRNA Cap 2´-O-Methyltransferase (NEB https://www.neb.com/en/#M0366) is required to generate Cap-1 structure that reduces cellular innate immune response when the RNA is used in vivo
  • Isolated from a recombinant source
  • Tested for the absence of endonucleases, exonucleases, RNases
  • Getting ready to scale up RNA synthesis? Download our new technical note “Scaling of High-Yield In vitro Transcription Reactions for Linear Increase of RNA Production” for a generalized set of recommendations for synthesizing high yields of RNA.
Catalog https://www.neb.com/en/# Concentration Size
M2080S 10,000 units/ml 400 units
Please enter a quantity for at least one size

Now available as a GMP-grade reagent. Learn more
Need a custom/large volume order? Contact us
  • Product Information

    Based on the Vaccinia virus Capping Enzyme (VCE), the Vaccinia Capping System provides the necessary components to add 7-methylguanylate cap structures (Cap-0) to the 5´end of RNA (1). In eukaryotes, these terminal cap structures are involved in stabilization (2), transport (3), and translation (4) of mRNAs. Enzymatic production of capped RNA is an easy way to improve the stability and translational competence of RNA used for in vitro translation, transfection, and microinjection. Alternatively, use of labeled GTP in a reaction provides a convenient way to label any RNA containing a 5´ terminal triphosphate.

    Vaccinia capping enzyme is composed of two subunits (D1 and D12). The D1 subunit carries three enzymatic activities (RNA triphosphatase, guanylyltransferase and guanine methyltransferase); all necessary for addition of a complete Cap-0 structure, m7Gppp5'N to 5' triphosphate RNA (5,6). In vitro transcripts can be capped in less than one hour in the presence of the capping enzyme, reaction buffer, GTP, and the methyl donor, SAM. Capping is nearly 100% efficient and all capped structures are added in the proper orientation, unlike co-transcriptional addition of some cap analogs (7).

    Figure 1. 5´ Cap Structure



    Schematic representation of mRNA 5´ cap structure indicating the 7-methylguanosine, shown in yellow, and the 5´ end of the mRNA, shown in blue. The 2´-O-methyl group present in Cap-1 and Cap-2 structures is shown in red.

    Product Source

    An E. coli strain that carries an engineered His-tagged Vaccine capping gene.
    This product is related to the following categories:
    RNA Capping
    • Reagents Supplied

      The following reagents are supplied with this product:

      NEB https://www.neb.com/en/# Component Name Component https://www.neb.com/en/# Stored at (°C) Amount Concentration
      • M2080S     -20    
          Vaccinia Capping System M2080SVIAL -20 1 x 0.04 ml 10,000 units/ml
          Capping Buffer B2080AVIAL -20 1 x 0.1 ml Not Applicable
          S-adenosylmethionine (SAM) B9003SVIAL -20 1 x 0.1 ml 32 mM
          GTP N2080AVIAL -20 1 x 0.05 ml 10 mM
    • Properties & Usage

      Unit Definition

      One unit of Vaccinia Capping Enzyme is defined as the amount of enzyme required to incorporate 10 pmol of (α32P) GTP into an 80 nt transcript in 1 hour at 37°C.

      Reaction Conditions

      1X Capping Buffer
      Supplement with 0.5 mM GTP and 0.1 mM S-adenosylmethionine (SAM)
      Incubate at 37°C

      1X Capping Buffer
      50 mM Tris-HCl
      5 mM KCl
      1 mM MgCl2
      1 mM DTT
      (pH 8 @ 25°C)

      Storage Buffer

      20 mM Tris-HCl
      100 mM NaCl
      1 mM DTT
      0.1 mM EDTA
      50% Glycerol
      0.1% (w/v) Triton® X-100
      pH 8 @ 25°C

    • Advantages and Features

      Application Features

      Capping mRNA prior to translation assays/in vitro translation
      Labeling 5´ end of mRNA
    • Related Products

    • Product Notes

      1. (read prior to setting up reaction)

        RNA used for capping reactions should be purified prior to use and suspended in nuclease-free water. EDTA should not be present and the solution should be free of salts.
      2. While RNase Inhibitor is not required, many users prefer to use it to enhance the stability of their RNA in solution. If this is desired, 0.5 µl of a standard RNase inhibitor prep (such as RNase Inhibitor, Murine, NEB https://www.neb.com/en/#M0314) can be added at the time of reaction set-up. The additional volume can be subtracted from the amount of H2O used in step 1 of both the capping and the labeling protocols.
      3. Heating the solution of RNA prior to incubation with the Vaccinia Capping Enzyme removes secondary structure on the 5´ end of the transcript. Extend time to 10 minutes for transcripts with known highly structured 5´ ends.
      4. SAM is unstable at pH 7–8, 37°C and should be mixed fresh prior to starting the reaction. We recommend determining how many reactions will be performed and diluting an aliquot of the 32 mM stock to 2 mM just prior to setting up the reactions. This "working stock" should be kept on ice to prevent degradation of SAM.
      5. For transcripts with known structured 5´ ends, the reaction time can be extended to 60 minutes to improve capping efficiency.
      6. For labeling the 5´ end, the total GTP concentration should be around 1–3X the molar concentration of mRNA in the reaction. The 10 mM stock can be diluted and a "spike" of hot GTP added to make the GTP mix.
    • References

      1. Shuman, S. (1990). J. Biol. Chem. 265, 11960-11966.
      2. Furiichi, Y. et al (1977). Nature. 266, 235-239.
      3. Lewis, J.D. and Izaurralde, E (1997). Eur. J. Biochem. 247, 461-469.
      4. Iizuka, N. et al. (1994). Mol. Cell. Biol. 14, 7322-7330.
      5. Guo, P. and Moss, B. (1990). Proc. Natl. Acad. Sci. 87, 4023-4027.
      6. Mao, X. and Shuman, S. (1994). J. Biol. Chem. 269, 24472-24479.
      7. Grudzien, E. et al. (2004). RNA. 10, 1479.
      8. Ramanathan, A. et al. (2016). Nucleic Acids Res. Sep 19; 44(16), 7511–7526. PubMedID: 27317694
  • Protocols, Manuals & Usage

  • FAQs & Troubleshooting

    • FAQs

    • Tech Tips

      It is important to ensure that the RNA is purified prior to use. It should be suspended in nuclease-free water free from EDTA and salts.
      Heating the RNA at 65°C for 5 minutes prior to setting up the reaction removes secondary structures on the 5´ end of the transcript. Extend time to 10 minutes for RNA with known highly structured 5’ ends.
      SAM is unstable at pH 7–8, 37°C. Hence, it should be diluted just prior to starting the reaction.
      We strongly recommend wearing gloves, using nuclease-free tubes and reagents, and thoroughly cleaning pipettes and bench surfaces to avoid RNase contamination.
  • Citations & Technical Literature

    • Citations

      Product Citation Tool

      Additional Citations

      • Wulf, Madalee; Buswell, John; Chan, Siuhong; Dai, Nan; Marks, Katherine; Tzertzinis, George; Whipple, Joe; Correa, Ivan; Schildkraut, Ira; (2019) The yeast scavenger decapping enzyme DcpS and its application for in vitro RNA recapping Sci Rep; 9 (1), 8594. PubMedID: 31197197, DOI: https://www.neb.com/en/10.1038/s41598-019-45083-5
      • Wulf, M.G., Maguire, S., Humbert, P., Dai, N., Bei, Y., Nichols, N.M., Correa, I.R., Jr., Guan, S (2019) Non templated addition and template switching by Moloney murine leukemia virus MMLV based reverse transcriptases co occur and compete with each other J Biol Chem; 294(48), 18220-18231.. PubMedID: 31640989, DOI: https://www.neb.com/en/10.1074/jbc.RA119.010676
    • Publications

      • Wulf, Madalee; Buswell, John; Chan, Siuhong; Dai, Nan; Marks, Katherine; Tzertzinis, George; Whipple, Joe; Correa, Ivan; Schildkraut, Ira; (2019) The yeast scavenger decapping enzyme DcpS and its application for in vitro RNA recapping Sci Rep; 9 (1), 8594. PubMedID: 31197197, DOI: https://www.neb.com/en/10.1038/s41598-019-45083-5
      • Wulf, M.G., Maguire, S., Humbert, P., Dai, N., Bei, Y., Nichols, N.M., Correa, I.R., Jr., Guan, S (2019) Non templated addition and template switching by Moloney murine leukemia virus MMLV based reverse transcriptases co occur and compete with each other J Biol Chem; 294(48), 18220-18231.. PubMedID: 31640989, DOI: https://www.neb.com/en/10.1074/jbc.RA119.010676

Ineligible item added to cart

Based on your Freezer Program type, you are trying to add a product to your cart that is either not allowed or not allowed with the existing contents of your cart. Please review and update your order accordingly. If you have any questions, please contact Customer Support at freezers@neb.com or 1-800-632-5227 x 8.

Continue

Choose your country

If you don&https://www.neb.com/en/#39;t see your country above, please visit our international site

Loading Spinner

Session Expired

You have been idle for more than 20 minutes, for your security you have been logged out. Please sign back in to continue your session.

Institution Changed

Your profile has been mapped to an Institution, please sign back for your profile updates to be completed.

Sign in to your NEB account

To save your cart and view previous orders, sign in to your NEB account. Adding products to your cart without being signed in will result in a loss of your cart when you do sign in or leave the site.

Sign In



Notes
  • (read prior to setting up reaction)

    RNA used for capping reactions should be purified prior to use and suspended in nuclease-free water. EDTA should not be present and the solution should be free of salts.
  • While RNase Inhibitor is not required, many users prefer to use it to enhance the stability of their RNA in solution. If this is desired, 0.5 µl of a standard RNase inhibitor prep (such as RNase Inhibitor, Murine, NEB #M0314) can be added at the time of reaction set-up. The additional volume can be subtracted from the amount of H2O used in step 1 of both the capping and the labeling protocols.
  • Heating the solution of RNA prior to incubation with the Vaccinia Capping Enzyme removes secondary structure on the 5´ end of the transcript. Extend time to 10 minutes for transcripts with known highly structured 5´ ends.
  • SAM is unstable at pH 7–8, 37°C and should be mixed fresh prior to starting the reaction. We recommend determining how many reactions will be performed and diluting an aliquot of the 32 mM stock to 2 mM just prior to setting up the reactions. This "working stock" should be kept on ice to prevent degradation of SAM.
  • For transcripts with known structured 5´ ends, the reaction time can be extended to 60 minutes to improve capping efficiency.
  • For labeling the 5´ end, the total GTP concentration should be around 1–3X the molar concentration of mRNA in the reaction. The 10 mM stock can be diluted and a "spike" of hot GTP added to make the GTP mix.
References
  • Shuman, S. (1990). J. Biol. Chem. 265, 11960-11966.
  • Furiichi, Y. et al (1977). Nature. 266, 235-239.
  • Lewis, J.D. and Izaurralde, E (1997). Eur. J. Biochem. 247, 461-469.
  • Iizuka, N. et al. (1994). Mol. Cell. Biol. 14, 7322-7330.
  • Guo, P. and Moss, B. (1990). Proc. Natl. Acad. Sci. 87, 4023-4027.
  • Mao, X. and Shuman, S. (1994). J. Biol. Chem. 269, 24472-24479.
  • Grudzien, E. et al. (2004). RNA. 10, 1479.
  • Ramanathan, A. et al. (2016). Nucleic Acids Res. Sep 19; 44(16), 7511–7526. PubMedID: 27317694
Tech Tips
  • It is important to ensure that the RNA is purified prior to use. It should be suspended in nuclease-free water free from EDTA and salts.
  • Heating the RNA at 65°C for 5 minutes prior to setting up the reaction removes secondary structures on the 5´ end of the transcript. Extend time to 10 minutes for RNA with known highly structured 5’ ends.
  • SAM is unstable at pH 7–8, 37°C. Hence, it should be diluted just prior to starting the reaction.
  • We strongly recommend wearing gloves, using nuclease-free tubes and reagents, and thoroughly cleaning pipettes and bench surfaces to avoid RNase contamination.
Additional Citations
  • Wulf, Madalee; Buswell, John; Chan, Siuhong; Dai, Nan; Marks, Katherine; Tzertzinis, George; Whipple, Joe; Correa, Ivan; Schildkraut, Ira; (2019) The yeast scavenger decapping enzyme DcpS and its application for in vitro RNA recapping Sci Rep 9 (1), 8594.PubMedID: 31197197, DOI: 10.1038/s41598-019-45083-5
  • Wulf, M.G., Maguire, S., Humbert, P., Dai, N., Bei, Y., Nichols, N.M., Correa, I.R., Jr., Guan, S (2019) Non templated addition and template switching by Moloney murine leukemia virus MMLV based reverse transcriptases co occur and compete with each other J Biol Chem 294(48), 18220-18231..PubMedID: 31640989, DOI: 10.1074/jbc.RA119.010676
Publications
  • Wulf, Madalee; Buswell, John; Chan, Siuhong; Dai, Nan; Marks, Katherine; Tzertzinis, George; Whipple, Joe; Correa, Ivan; Schildkraut, Ira; (2019). The yeast scavenger decapping enzyme DcpS and its application for in vitro RNA recapping Sci Rep. 9 (1), 8594.PubMedID: 31197197, DOI: 10.1038/s41598-019-45083-5
  • Wulf, M.G., Maguire, S., Humbert, P., Dai, N., Bei, Y., Nichols, N.M., Correa, I.R., Jr., Guan, S (2019). Non templated addition and template switching by Moloney murine leukemia virus MMLV based reverse transcriptases co occur and compete with each other J Biol Chem. 294(48), 18220-18231..PubMedID: 31640989, DOI: 10.1074/jbc.RA119.010676
Quality Control Assay
Quality Control tests are performed on each new lot of NEB product to meet the specifications designated for it. Specifications and individual lot data from the tests that are performed for this particular product can be found and downloaded on the Product Specification Sheet, Certificate of Analysis, data card or product manual. Further information regarding NEB product quality can be found here.
Specifications
The Specification sheet is a document that includes the storage temperature, shelf life and the specifications designated for the product. The following file naming structure is used to name these document files: [Product Number]_[Size]_[Version]
Legal And Disclaimer

Products and content are covered by one or more patents, trademarks and/or copyrights owned or controlled by New England Biolabs, Inc (NEB). The use of trademark symbols does not necessarily indicate that the name is trademarked in the country where it is being read; it indicates where the content was originally developed. The use of this product may require the buyer to obtain additional third-party intellectual property rights for certain applications. For more information, please email busdev@neb.com.

This product is intended for research purposes only. This product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

New England Biolabs (NEB) is committed to practicing ethical science – we believe it is our job as researchers to ask the important questions that when answered will help preserve our quality of life and the world that we live in. However, this research should always be done in safe and ethical manner. Learn more.

Top